UK markets open in 6 hours 53 minutes
  • NIKKEI 225

    30,500.05
    +176.75 (+0.58%)
     
  • HANG SENG

    24,920.76
    +252.96 (+1.03%)
     
  • CRUDE OIL

    71.66
    -0.31 (-0.43%)
     
  • GOLD FUTURES

    1,754.20
    +2.80 (+0.16%)
     
  • DOW

    34,584.88
    -166.42 (-0.48%)
     
  • BTC-GBP

    34,405.62
    -922.76 (-2.61%)
     
  • CMC Crypto 200

    1,185.25
    -40.28 (-3.29%)
     
  • ^IXIC

    15,043.97
    -137.93 (-0.91%)
     
  • ^FTAS

    4,023.33
    -28.11 (-0.69%)
     

Hypoparathyroidism Epidemiology Research Report 2021-2030 - ResearchAndMarkets.com

·4-min read

DUBLIN, July 28, 2021--(BUSINESS WIRE)--The "Hypoparathyroidism - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This 'Hypoparathyroidism Epidemiology Forecast-2030' report delivers an in-depth understanding of the Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Hypoparathyroidism Detailed Epidemiology Segmentation

  • The total prevalent population of hypoparathyroidism in the 7MM ranges from 262,542 in 2020 growing at a CAGR of 1.22% during the study period [2018-2030].

  • Among the European five countries, Germany had the highest prevalent population of hypoparathyroidism with 28,604 cases, followed by UK and France in 2020. On the other hand, Spain had the lowest prevalent population.

  • Japan had 33,276 prevalent cases of hypoparathyroidism in 2020.

  • As per the analysis, a higher percentage of prevalence was observed for females, in comparison to males, in all the 7MM countries.

  • According to the analysis, it has been observed that hypoparathyroidism prevalence varied across the 7MM countries, based on the age-specific prevalence of the disease. For instance, the highest proportion was observed in the 65+ Years age group in the US, while in the EU-5 countries, people aged 55-64 Years accounted for the maximum patient pool.

  • Among the major types of hypoparathyroidism, i.e., Chronic and transient hypoparathyroidism, the former one accounts for a higher number of prevalent cases of hypoparathyroidism.

Scope of the Report

  • The report covers the descriptive overview of Hypoparathyroidism, explaining its causes, symptoms, pathophysiology, and genetic basis.

  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • The report assesses the disease risk and burden and highlights the unmet needs of Hypoparathyroidism.

  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Hypoparathyroidism, Diagnosed Prevalent Cases of Hypoparathyroidism, Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism, Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism, Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism, and Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism.

Key Topics Covered:

1 Key Insights

2 Report Introduction

3 Executive Summary of Hypoparathyroidism

4 Key Events

5 Disease Background and Overview

5.1 Introduction

5.2 Causes of Hypoparathyroidism

5.3 Symptoms of Hypoparathyroidism

5.4 Mechanisms/pathophysiology Hypoparathyroidism

5.5 Diagnosis of Hypoparathyroidism

5.5.1 Guidelines for diagnosis and evaluation

5.5.2 European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults

6 Treatment

6.1 Management of Hypoparathyroidism: Summary Statement and Guidelines

6.2 European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism (HypoPT) in adults

6.3 The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism

6.4 Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 Epidemiology Methodology

7.3 Total Prevalent Cases of Hypoparathyroidism in the 7MM

7.4 Total Diagnosed Prevalent Cases of Hypoparathyroidism in the 7MM

7.5 Epidemiology of Hypoparathyroidism

7.6 The United States

7.6.1 Prevalent Cases of Hypoparathyroidism in the United States

7.6.2 Diagnosed Prevalent Cases of Hypoparathyroidism in the United States

7.6.3 Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States

7.6.4 Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States

7.6.5 Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States

7.6.6 Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States

7.7 EU5

7.8 Japan

8 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gltxt4

View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005524/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting